BUZZ-Rezolute rises as drug shows promise for rare low blood sugar disorders

Reuters01-07
BUZZ-Rezolute rises as drug shows promise for rare low blood sugar disorders

** Shares of drug developer Rezolute RZLT.O rise 2.1% to $1.95 premarket

** Co says late-stage trial of ersodetug in congenital hyperinsulinism missed main goals but showed drug activity

** Congenital HI causes frequent severe drops in blood sugar; all 59 patients opted for extension study, RZLT says

** Some children stopped other treatments, relying only on ersodetug, co says

** Expanded access program in tumor-related HI saw 75% patients stop hospital glucose infusions, RZLT says

** Co plans FDA meeting early this year

** Ersodetug aims to block excess insulin effects; drug generally well-tolerated so far, co says

** As of last close, stock down ~19% over the past year

(Reporting by Sahil Pandey in Bengaluru)

((Sahil.Pandey@thomsonreuters.com))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment